Recent Investment Analysts’ Ratings Changes for Nuvalent (NUVL)

A number of research firms have changed their ratings and price targets for Nuvalent (NASDAQ: NUVL):

• 6/24/2026 – Nuvalent was downgraded by Sanford C. Bernstein from “outperform” to “market perform”. They now have a $124.00 price target on the stock, down from $172.00.
• 6/10/2026 – Nuvalent had its “outperform” rating reaffirmed by Sanford C. Bernstein.
• 6/10/2026 – Nuvalent was downgraded by Guggenheim from “buy” to “neutral”. They now have a $124.00 price target on the stock, down from $151.00.
• 6/10/2026 – Nuvalent was downgraded by UBS Group AG from “buy” to “neutral”. They now have a $124.00 price target on the stock, down from $138.00.
• 6/10/2026 – Nuvalent was downgraded by UBS Group AG from “buy” to “neutral”. They now have a $124.00 price target on the stock, down from $138.00.
• 6/9/2026 – Nuvalent was downgraded by Truist Financial Corporation from “buy” to “hold”. They now have a $124.00 price target on the stock, down from $140.00.
• 6/9/2026 – Nuvalent was downgraded by TD Cowen from “buy” to “hold”. They now have a $124.00 price target on the stock.
• 6/9/2026 – Nuvalent had its “equal weight” rating reaffirmed by Barclays PLC. They now have a $124.00 price target on the stock, down from $152.00.
• 6/9/2026 – Nuvalent was given a new $122.85 price target by Robert W. Baird.
• 6/9/2026 – Nuvalent was given a new $124.00 price target by Stifel Nicolaus.
• 6/9/2026 – Nuvalent was downgraded by Raymond James Financial, Inc. from “outperform” to “market perform”.
• 6/9/2026 – Nuvalent had its “equal weight” rating reaffirmed by Wells Fargo & Company. They now have a $124.00 price target on the stock, up from $116.00.
• 6/9/2026 – Nuvalent was downgraded by Piper Sandler from “overweight” to “neutral”. They now have a $124.00 price target on the stock.
• 6/9/2026 – Nuvalent was downgraded by Cantor Fitzgerald from “overweight” to “neutral”.
• 6/9/2026 – Nuvalent was downgraded by Truist Financial Corporation from “buy” to “hold”. They now have a $124.00 price target on the stock, down from $140.00.
• 6/9/2026 – Nuvalent was downgraded by Canaccord Genuity Group Inc. from “strong-buy” to “hold”.
• 6/9/2026 – Nuvalent was downgraded by Barclays PLC from “strong-buy” to “hold”.
• 6/9/2026 – Nuvalent was downgraded by Robert W. Baird from “strong-buy” to “hold”.
• 6/9/2026 – Nuvalent was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $124.00 price target on the stock, up from $116.00.
• 6/9/2026 – Nuvalent was downgraded by HC Wainwright from “buy” to “neutral”. They now have a $124.00 price target on the stock.
• 6/9/2026 – Nuvalent was downgraded by Lifesci Capital from “outperform” to “hold”. They now have a $124.00 price target on the stock.
• 6/9/2026 – Nuvalent was downgraded by Wedbush from “outperform” to “neutral”. They now have a $124.00 price target on the stock, down from $125.00.
• 6/3/2026 – Nuvalent was given a new $165.00 price target by Leerink Partners.
• 6/2/2026 – Nuvalent had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 5/28/2026 – Nuvalent had its “outperform” rating reaffirmed by Wedbush. They now have a $125.00 price target on the stock.
• 5/21/2026 – Nuvalent is now covered by Sanford C. Bernstein. They set an “outperform” rating and a $189.00 price target on the stock.
• 5/21/2026 – Nuvalent is now covered by Sanford C. Bernstein. They set an “outperform” rating and a $189.00 price target on the stock.
• 5/21/2026 – Nuvalent was upgraded by Sanford C. Bernstein to “strong-buy”.

Insider Activity at Nuvalent

In other Nuvalent news, CEO James Richard Porter sold 30,000 shares of Nuvalent stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $88.53, for a total value of $2,655,900.00. Following the completion of the transaction, the chief executive officer directly owned 324,879 shares of the company’s stock, valued at $28,761,537.87. The trade was a 8.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Alexandra Balcom sold 11,430 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $98.69, for a total transaction of $1,128,026.70. Following the sale, the chief financial officer owned 85,533 shares in the company, valued at $8,441,251.77. This trade represents a 11.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 126,953 shares of company stock worth $12,612,264 over the last quarter. Company insiders own 5.02% of the company’s stock.

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.